Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause
- PMID: 10584677
- DOI: 10.1002/1531-8257(199911)14:6<1008::aid-mds1015>3.0.co;2-e
Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause
Abstract
Circumstantial evidence suggests that increased apoptosis is responsible for the loss of dopaminergic nigrostriatal neurons in Parkinson's disease (PD). It is impossible to perform high-quality studies on human postmortem material because of the low quality of tissue preservation, and the fact that apoptosis has a duration of only hours, and that the duration of the agonal period itself will lead to massive neuronal cell death. We measured, as epiphenomenon of neuronal cell death ex vivo, the Annexin V concentration in cerebrospinal fluid (CSF) in patients with PD and control subjects. The Annexin V concentration in CSF of patients with PD was significantly lower compared with control subjects. Annexin V concentrations of the CSF did not correlate with dementia, duration of symptoms, age, sex, or treatment of PD. The rationale for measurement of Annexin V in CSF is the fact that Annexin V adheres to dying cells. It is tempting to suppose that the decrease of Annexin V in CSF of PD is the result of consumption of this protein during neuronal apoptosis as has been demonstrated to occur in the midbrain in PD.
Similar articles
-
Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.Arch Neurol. 1999 Feb;56(2):194-200. doi: 10.1001/archneur.56.2.194. Arch Neurol. 1999. PMID: 10025424
-
Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.Eur J Neurol. 2014 Mar;21(3):388-94. doi: 10.1111/ene.12176. Epub 2013 Apr 30. Eur J Neurol. 2014. PMID: 23631635
-
In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.Brain. 2016 Jul;139(Pt 7):2039-49. doi: 10.1093/brain/aww098. Epub 2016 May 5. Brain. 2016. PMID: 27190023
-
Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease.Neurotoxicol Teratol. 2002 Sep-Oct;24(5):579-91. doi: 10.1016/s0892-0362(02)00211-8. Neurotoxicol Teratol. 2002. PMID: 12200189 Review.
-
Inflammatory process in Parkinson's disease: role for cytokines.Curr Pharm Des. 2005;11(8):999-1016. doi: 10.2174/1381612053381620. Curr Pharm Des. 2005. PMID: 15777250 Review.
Cited by
-
Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells.Neurol Sci. 2011 Apr;32(2):221-8. doi: 10.1007/s10072-010-0340-3. Epub 2010 Jun 19. Neurol Sci. 2011. PMID: 20563739
-
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.Neurobiol Dis. 2010 Sep;39(3):229-41. doi: 10.1016/j.nbd.2010.04.020. Epub 2010 May 6. Neurobiol Dis. 2010. PMID: 20451609 Free PMC article. Review.
-
Proteome analysis of human substantia nigra in Parkinson's disease.Proteome Sci. 2008 Feb 14;6:8. doi: 10.1186/1477-5956-6-8. Proteome Sci. 2008. PMID: 18275612 Free PMC article.
-
Leveraging Plasma Membrane Repair Therapeutics for Treating Neurodegenerative Diseases.Cells. 2023 Jun 18;12(12):1660. doi: 10.3390/cells12121660. Cells. 2023. PMID: 37371130 Free PMC article. Review.
-
New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology.Pharmaceuticals (Basel). 2024 Jul 24;17(8):979. doi: 10.3390/ph17080979. Pharmaceuticals (Basel). 2024. PMID: 39204083 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical